From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance

Cellular and Molecular Life Sciences

Volumn 58, Issue 7, 2001, Pages 931-959

  Litman, T ^a   Druley, T E ^b   Stein, W D ^c   Bates, S E ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABC transporter; ATPase; Mitoxantrone resistance protein (MXR, BCRP, ABCP, ABCG2); Multidrug resistance; Multidrug resistance associated protein (MRP); P glycoprotein (MDR1)

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ANTHRACENE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISANTRENE; CALCIUM CHANNEL BLOCKING AGENT; CALMODULIN INHIBITOR; CAMPTOTHECIN DERIVATIVE; COLCHICINE; DACTINOMYCIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ELACRIDAR; EPIPODOPHYLLOTOXIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; HOE 33342; IRINOTECAN; MITOXANTRONE; MITOXANTRONE RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PROTEINASE INHIBITOR; TENIPOSIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

BINDING AFFINITY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME SPECIFICITY; MULTIDRUG RESISTANCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

EID: 0034947674     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000912     Document Type: Review

References (235)

1. A family of closely related ATP-binding subunits from prokaryotic and eukaryotic cells
2. Distantly related sequences in the α- and β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold
3. Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo
4. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells
5. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloides in vivo. A new treatment principle
6. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies
7. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts
8. Drug resistance and membrane alteration in mutants of mammalian cells
9. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
10. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
11. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins
12. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
13. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
14. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium channel blockers
15. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells
16. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase
17. ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines
18. ATP hydrolysis by multidrug-resistance protein from Chinese hamster ovary cells
19. Partial purification and reconstitution of the human multidrug-resistance pump: Characterization of the drug-stimulatable ATP hydrolysis
20. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein
21. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
22. Altered drug-stimulated AT-Pase activity in mutants of the human multidrug resistance protein
23. Pharmacology of drugs that alter multidrug resistance in cancer
24. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12
25. Identification of residues in the drug-binding domain of human P-glycoprotein
26. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane
27. The packing of the trans-membrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis
28. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains
29. Secondary and tertiary structure changes of reconstituted P-glycoprotein. A Fourier transform attenuated total reflection infrared spectroscopy analysis
30. Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis
31. Conformational changes of P-glycoprotein by nucleotide binding
32. Dissection of drug-binding-induced conformational changes in P-glycoprotein
33. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody
34. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies
35. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity
36. Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein
37. The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2
38. Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody
39. Tumour cell resistance to anthracyclines: A review
40. Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines
41. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity
42. P-glycoprotein mediates profound resistance to bisantrene
43. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
44. ATP-dependent transport of vinblastine in vesicles from human multi-drug-resistant cells
45. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines
46. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines
47. Comparison of the accumulation of the epipodophyllotoxins VP-16 and VM-26 in a sensitive and a multidrug-resistant Ehrlich ascites tumour cell line detected by HPLC
48. Transport properties of P-glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells
49. Modulation of the multidrug resistance phenotype
50. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia
51. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
52. Calcein accumulation as a fluorometric functional assay of the multidrug transporter
53. Constitutive expression of P-glycoprotein as a determinant of loading with fluorescent calcium probes
54. Fluorescent cellular indicators are extruded by the multidrug resistance protein
55. Characterization of multidrug resistance by fluorescent dyes
56. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein
57. Correlation between potency of calmodulin inhibitors and effects on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells
58. Structural features determining activity of phenotiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance
59. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines
60. Tamoxifen-resistant human breast cancer cell growth: Inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13
61. Amiodarone-induced enhancement of doxorubicin and 4′-deoxyrubicin cytotoxicity to rat colon cancer cells in vitro and in vivo
62. Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance
63. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
64. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells
65. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus
66. Steroid transport, accumulation, and antagonism of P-glcoprotein in multidrug-resistant cells
67. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues
68. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129
69. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
70. Mobile ionophores are a novel class of P-glycoprotein inhibitors
71. Probing the interaction of the multidrug-resistance phenotype with the polypeptide ionophore gramicidin D via functional channel formation
72. High-pressure liquid chromatographic determination of promethazine plasma levels in the dog after oral, intramuscular and intravenous dosage
73. Terfenadine (Seldane): A new drug for restoring sensitivity to multidrug resistant cancer cells
74. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria
75. The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter
76. Plasma levels, psychophysiological variables and clinical response to amitriptyline
77. Dipyridamole enhancement of etoposide sensitivity
78. Fucidin therapy in carcinoma of the breast. (Preliminary report)
79. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter
80. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor
81. Differential modulation of P-glycoprotein transport by protein kinase inhibition
82. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen
83. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen
84. P-glycoprotein substrates and antagonists cluster into two distinct groups
85. Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity
86. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity
87. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
88. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site
89. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
90. Communication between multiple drug binding sites on P-glycoprotein
91. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells
92. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
93. Characterization of the azidopine and vinblastine binding site of P-glycoprotein
94. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
95. Mutually co-operative interactions between modulators of P-glycoprotein
96. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal
97. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity
98. P-glycoprotein mediated colchicine resistance in different cell lines correlates with the effects of colchicine on P-glycoprotein conformation
99. Interaction of combinations of drugs, chemosensitizers and peptides with the P-glycoprotein multidrug transporter
100. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells
101. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators
102. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene
103. Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection
104. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer
105. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein
106. Specific drug binding by purified lipid-reconstituted P-glycoprotein: Dependence on the lipid composition
107. Effects of non-ionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance
108. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein
109. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface
110. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter
111. Involvement of cytoplasmic factors regulating the membrane orientation of P-glycoprotein sequences
112. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: Effects of verapamil and other drugs
113. Effect of duration of exposure to verapamil on vincristine activity against multi-drug-resistant human leukemic cell lines
114. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR3
115. 3H]vinblastine transport by isolated vesicles
116. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells
117. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein
118. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells
119. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells
120. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter
121. Drug accumulation in the presence of the multidrug resistance pump: Dissociation between verapamil accumulation and the action of P-glycoprotein
122. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
123. Mechanism of action of P-glycoprotein in relation to passive membrane permeation
124. The role of passive transbilayer drug movement in multidrug resistance and its modulation
125. Human P-glycoprotein transports cyclosporin A and FK506
126. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein
127. P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules
128. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from funcional interactions between various drugs
129. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction
130. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein
131. Study of sodium orthovanadate as a reverser of multi-drug resistance on lymphoblastic leukemic CEM/VLB100 cells
132. Covalent inhibitors of P-glycoprotein ATPase activity
133. Inhibition of myosin ATPase by vanadate ion
134. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site
135. Both P-glycoprotein nucleotide-binding sites are catalytically active
136. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities
137. Both ATP sites of human P-glycoprotein are essential but not symmetric
138. Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1
139. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state
140. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis
141. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein
142. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein
143. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein
144. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites
145. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance
146. Membrane topology of a cysteine-less mutant of human P-glycoprotein
147. The catalytic cycle of P-glycoprotein
148. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein
149. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism
150. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein
151. Genetic polymorphism in P-glycoprotein: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors
152. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein
153. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex
154. Modulation of the multidrug, resistance p-glycoprotein: Detection with technetium-99m-sestamibi in vivo
155. 99mTc-sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours
156. Detection of in vivo p-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi
157. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
158. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
159. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
160. A family of drug transporters: The multidrug resistance-associated proteins
161. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells
162. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
163. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
164. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents
165. MRP3, an organic anion transporter able to transport anti-cancer drugs
166. Function, evolution and structure of multidrug resistance protein (MRP)
167. Structural, mechanistic and clinical aspects of MRP1
168. r 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells
169. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry
170. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein
171. Transport of glutathione, glucuronate and sulfate conjugates by the MRP gene-encoded conjugate export pump
172. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione
173. Evidence that the multidrug resistance protein (MRP) functions as a co- transporter of glutathione and natural product toxins
174. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
175. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers
176. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
177. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells
178. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
179. MRP expression in acute myeloid leukemia. An update
180. Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response
181. Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung
182. Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer
183. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer
184. Expression of the multi-drug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer
185. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer
186. MRP and MDR1 gene expression in primary breast carcinomas
187. Clinical significance of the increased multi-drug resistance-associated protein (MRP) gene expression in patients with primary breast cancer
188. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients
189. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2 and lung resistance protein as prognostic factors in ovarian carcinoma
190. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
191. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer
192. Extensive contribution of the multidrug transporters p-glycoprotein and Mrp1 to basal drug resistance
193. Chemosensitization and drug accumulation effects of VX-710, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
194. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P
195. The leukotriene LTC4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance
196. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation
197. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
198. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
199. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells
200. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene in human cancer cell lines
201. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions
202. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when over-expressed in human embryonic kidney 293 cells
203. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity and MRP2-mediated drug resistance
204. Hepatic secretion of conjugated drugs and endogenous substances
205. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells
206. MRP3, a new ATP-binding cassette protein localized to the canalicular domain of the hepatocyte
207. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane
208. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs
209. Transport function and hepatocellular localization of mrp6 in rat liver
210. A multidrug resistance transporter from human MCF-7 breast cancer cells
211. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein
212. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
213. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells. Demonstration of homology to ABC transport genes
214. ABC transporters involved in transport of eye pigment precursors in Drosophila melanogaster
215. The transporters associated with antigen presentation
216. The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells
217. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro
218. The mouse bcrp/mxr/abcp gene: Amplification and overexperssion in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
219. Identification of 18 mouse ABC genes and characterization of the ABC superfamily in Mus musculus
220. An ATP-binding cassette gene (ABCG5) closely related to the multidrug transporter (MXR/ABCP) ABCG2 has an unusual ATP-binding domain
221. Amplification of q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines
222. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
223. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
224. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells
225. The multidrug resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
226. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane
227. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
228. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein
229. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C
230. Fumitremorgin C analogs that reverse mitoxantrone resistance in human colon carcinoma cells
231. Inhibition of BCRP-mediated drug efflux by fumit-remorgin-type indolyl diketopiperazines
232. Breast cancer resistance protein (BCRP) associated drug export and p53 in-activation impact flavopiridol (FLA) antitumor activity
233. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan